Pirfenidone: Antifibrotic agent for idiopathic pulmonary fibrosis

Expert Review of Respiratory Medicine

Volumn 4, Issue 3, 2010, Pages 301-310

  Azuma, Arata ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cytokine; Desaturation; Idiopathic pulmonary fibrosis; IPF; Pirfenidone; Pulmonary function; Vital capacity

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; GAMMA1B INTERFERON; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE;

ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHOTOSENSITIVITY; POSTMARKETING SURVEILLANCE; REVIEW; SINGLE DRUG DOSE; STOMACH DISCOMFORT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77953261195     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.32     Document Type: Review

References (34)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. ATS and ERS. Am. J. Respir. Crit. Care Med. 161, 646-664 (2000).
2. The Japanese Respiratory Society, Committee for Formulation of Diffuse Pulmonary Disease Diagnosis and Treatment Guidelines: Idiopathic Interstitial Pneumonias - Guide to Diagnosis and Treatment. The Japanese Respiratory Society, Nankodo, Tokyo (2004) (In Japanese).
3. Ohno S, Nakaya T, Bando M, Sugiyama Y. Nationwide epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records. Records of Ministry of Health, Labor and Welfare of Japan in 2006, Japan, 46-54 (2007).
4. Chiba H, Hayashi N, Takahashi H. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido. Records of Ministry of Health, Labor and Welfare of Japan in 2008, Japan, 39-46 (2009).
5. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174, 810-816 (2006).
6. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon g-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341(17), 1264-1269 (1999).
7. Azuma A, Usuki J. Novel therapy for idiopathic pulmonary fibrosis - how to evaluate the efficacy? Respir. Med. 1, 75-81 (2008).
8. Margolin SB, Lefkowitz S. Pirfenidone: a novel pharmacologic agent for prevention and resolution of lung fibrosis. FASEB J. 8, A382 (1994).
9. Pirespa® , package insert. Shionogi & Co., Ltd, Japan.
10. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125(6), 779-785 (1995).
11. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291(1), 367-373 (1999). (Pubitemid 29451612)
12. Tada S, Nakamuta M, Enjoji M et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. 28(7), 522-527 (2001).
13. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 54(1), 99-109 (1998).
14. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol. 276(2), L311-L318 (1999). (Pubitemid 29102273)
15. Kakugawa T, Mukae H, Hayashi T et al. Pirfenidone attenuates expression of HSP47 in murine bleomysin-induced pulmonary fibrosis. Eur. Respir. J. 24(1), 57-65 (2004).
16. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-a, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. 446(1-3), 167-176 (2002).
17. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 170(3), 655-663 (1989).
18. Arai T, Abe K, Matsuoka H et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 278, L914-L922 (2000).
19. Oku H, Shimizu T, Kawabata T et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 590, 400-408 (2008).
20. Internal data of Shiongi and Co., Ltd. [In vitro study of pirfenidone in cultured cell lines.] [Reference No. 200801770] (Article in Japanese).
21. Mitani Y, Sato K, Muramoto Y et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem. Biophys. Res. Commun. 372, 19-23 (2008).
22. Oku H. 7. A novel antifibrotic agent pirfenidone, 1) Antifibrotic mechanism of pirfenidone. Medicine Drug J. 45(7), 120-125 (2009).
23. Rubino CM, Bhavnani SM, Ambrose PG et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm. Pharmacol. Ther. 22, 279-285 (2009).
24. Internal data of Shiongi and Co., Ltd. (Identification of CYP molecular species involved in oxidative metabolism) [Reference No. 200801762] (Article in Japanese).
25. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159, 1061-1069 (1999).
26. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 41, 1118-1123 (2002).
27. Azuma A, Nukiwa T, Tsuboi E et al.; members of Research Group for Diffuse Lung Diseases in Japan. A double blind and placebo-controlled clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171, 1040-1047 (2005).
28. Homma Y, Saiki S, Doi O et al. Clinical Diagnostic Criteria for Idiopathic Interstitial Pneumonia (3rd Revised Ed.). Diffuse Pulmonary Disease Research Group's, The Ministry of Health and Welfare of Japan, Japan, 83-88 (1992)
29. Taniguchi H, Ebina M, Knodoh Y et al.; Pirfenidone Clinical Study Group in Japan. Pirfenidone in Idiopathic Pulmonary Fibrosis: a Phase III clinical trial in Japan. Eur. Respir. J. 35, 821-829 (2010).
30. Ebina M, Kimura Y, Ohta H et al.; Clinical Study Group of Pirfenidone in Japan. Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis. Presented at: ERS 19th Annual Congress. Vienna, Austria, 12-16 September 2009 (Poster 666).
31. Noble PW, Albera C, Bradford W et al. The CAPACITY (CAP) trials: randomized, double-blind, placebo-controlled, Phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). Presented at: American Thoracic Society Annual Conference. San Diego, CA, USA, 15-20 May 2009 (Abstract 216).
32. de Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat. Drug Discov. 9, 129-140 (2010).
33. de Bois R, Albera C, Bradford W et al. Pirfenidone treatment for IPF comprehensive analysis of safety. Presented at: ERS 19th Annual Congress. Vienna, Austria, 12-16 September 2009 (Abstract 2823).
34. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2229-2242 (2005).